Optibiotix Health Share Discussion Threads

[whl2] 03/3/2017 17:18

nice 140k buy at the end

OOPS Might have been a late trade from yesterday

[michaelmouse] 03/3/2017 16:27

sukithedog - They've brought in £80,000 of revenues to date. Get real. This company will need massive fund raisings, the IP is worth jack sh*t if you've run out of money. They need all their paid pimps to try and keep the share price here to avoid catastrophic dilution.

In time and after constant disappointments and dilutions the share price will eventually fall back to 8p or below, I've seen it time and time again with story stocks like Opti.

If they announce a contract with all the financial details in the many multi-millions of pounds then I might reconsider, but even then at the current market cap. at least one such contract is already priced in.

Aimho of course.

[sukithedog] 03/3/2017 16:02

Michael - yes nothing going for opti :-)

IP: 45 patents / 15 families, 8 strain deposits, 7 trademarks
Commercial partners in place for all platforms with global brands

[michaelmouse] 03/3/2017 15:46

Absolutely loveandmoney1.

In time OptiBiotix will be back at its placing price of 8p.

Story stock with nothing to back up a ridiculous valuation. Ludicrous.

Tick tock.

[onedayrodders] 03/3/2017 14:32

nice ... as SOH has said repeatedly over the last few years ..we are ahead of the game

[scotty1] 03/3/2017 14:14

Tweaks Here and There to the Microbiome

Mar 02, 2017

Dozens of companies and researchers are focusing on developing products aimed at altering the human microbiome, New Scientist writes. The Janssen Human Microbiome Institute's Dirk Gevers tells it that there's more than a billion dollars invested in the field.

Some of drugs aimed at changing the gut or skin microbiome are already on the market as food supplements or cosmetics, New Scientist adds. For example, it says OptiBiotix sells snack bars that influence glucose metabolism, while Microbiome Therapeutics is to begin offering a smoothie mix later this year to regulate blood sugar. Similarly, AOBiome has been testing a spray to control acne.

Other new microbiome-focused drugs under development draw on older therapies, like fecal microbiome transplants for Clostridium difficile infections, for inspiration, it adds. At the University of Guelph, for instance, Emma Allen-Vercoe is attempting to tease out which bacteria are the ones needed to have the beneficial effect so that they can be put into a capsule, while others are trying to find ingredients that boost the growth of bacteria, such as those that digest lactose, for people who cannot digest dairy, New Scientist says.

"This field is moving faster than any other field we've seen," Gevers adds.

hxxps://www.genomeweb.com/scan/tweaks-here-and-there-microbiome

[daniel levi bmd] 03/3/2017 14:11

FYI

Zenith Energy Update. 600 bopd soon?

Dan
x

[onedayrodders] 03/3/2017 14:10

disappointed .. she doesn't look qualified enough for me


;o)

[primal123] 03/3/2017 14:04

Cheers mouse.

[mouse20] 03/3/2017 14:01

Primal, its at Companies House. She is also a fellow director with Martin Hunt at Videregen.

[primal123] 03/3/2017 13:58

Do you mind if I ask where you saw this mouse?

[mouse20] 03/3/2017 13:52

See things are much rosier now we have had concrete news from puggs.

Also a new director for our skin company, dr Catherine Prescott, appointed on 1st March.

Cathy brings over 20 years’ experience working within the life sciences sector including academia, business, financial services and venture capital. She is the Founder Director of Biolatris Ltd. and Co-founder Director of Quartet Innovation Partners Ltd. Cathy is a member of the Worcester Polytechnic Institute (USA) Life Sciences Advisory Board and a member of the Board of Trustees for the charity The International Medical Education Trust 2000. Cathy is involved in developing and implementing innovative finance and business models for emerging and disruptive sectors. She is a respected opinion leader within the stem cell and regenerative medicine business sector, and co-editor of the book ‘The Delivery of Regenerative Medicines and their Impact on Healthcare’ (CRC Press). She is also a mentor to the Centre for Entrepreneurial Learning summer business school (Cambridge University), Senior Associate for the Masters in Bioscience (Cambridge University), PhD examiner (Cambridge University) and mentor to the Royal Academy of Engineering entrepreneur awards scheme. Cathy is the author of peer-reviewed publications and invited speaker at national and international conferences serving both the life-science and financial services sectors (Actuarial Profession, insurer and underwriting conferences)

[pugg1ey] 03/3/2017 13:05

hxxp://www.concreteproducts.com/news.html

I'll get my coat

[mouse20] 03/3/2017 12:55

I'm getting a bit fed up of all these buying opportunities. I would prefer concrete news now.

[judijudi] 03/3/2017 12:31

I might add if we go to mid 60's

[diamond fibre] 03/3/2017 09:40

One of them was mine.

[parob] 03/3/2017 09:20

I disagree JH, we've had some decent buying this week, including a 50K chunk yesterday. Its the daily large dumper we've had to contend with which is holding us back. They will run out at some point!2 X 20K buys just gone through on Nex exchange.

[john henry] 03/3/2017 08:33

Technically, the share price is finding resistance again at the 50 day average. Has been struggling to break back above. The 50 has been strong resistance for many months, recently broke above but failed to support during the recent correction. Really needs to break back above to gain any momentum.Sellers have been back in force recently with very little buying.

[elrico] 02/3/2017 20:32

Ah, Mazzstar....still upset with me then. Now it makes sense. :-D

[parob] 02/3/2017 20:06

A fantastic response to Percival (aka mazzstar) from Dalester over on LSE just now:

"Having spent a number of years working in FMCG for Procter & Gamble, I didn't put my hard-earned in here to make a few quid from the first product in what looks to be developing as a massive portfolio of products suitable for addition to a vast range of products, many of which are currently unimaginable.

For perspective, there are over 100 food and beverage producing companies in the UK and Ireland with turnovers of £100m or more. There are probably a 1000 in the USA and 10s of thousands around the world. Opti is not just producing a new yoghurt, or a new flavour, it is developing a whole new category of much-needed food and drink products which will have a lasting beneficial effect on the health of billions of people.

Of course, distributors will be required, more-so than individual producers. Who in their right mind would allow a single company to gain exclusive use of a product capable of being licensed to 100s? Why would you put eggs as valuable as these in one basket? Think of any major food producer and you will recognise an opportunity to place OPTI products inside their tins, packets and bottles. "OPTI inside" will, in time, become as ubiquitous as "Intel Inside". Opti products offer huge differentiation to thousands of producers, all of whom spend millions advertising small changes in formulation or packaging and for whom there is genuinely little actual product difference.

OPTI is a game changer. Getting started may be the equivalent of kick-starting a jumbo jet, but once it starts to roll down the runway it will eventually climb like an F15 on steroids. I am not at all upset that P&G seems to be off the radar, there are literally thousands of other companies and thousands of products that can and in time, will benefit."

[michaelamouse] 02/3/2017 18:00

Darling you are so sweet, hugs and kisses




















































































































































































































night lover